Brad Watts, senior vice president at the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC), oversees the center’s day-to-day operations. He also leads the development and implementation of the Chamber’s U.S. and global intellectual property (IP) agenda to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
Watts previously served as the Republican chief counsel on the Senate Judiciary Committee Subcommittee on Intellectual Property. There he was responsible for planning and implementing Senator Thom Tillis’ (R-NC) and the Republican party’s legislative portfolio on all aspects of IP law.
In the 116th Congress, when Senator Tillis was chairman of the subcommittee, Watts served as majority chief counsel and staff director for the Senate Judiciary Committee Subcommittee on Intellectual Property. He was responsible for implementing the senator’s legislative and oversight agenda on all aspects of America’s innovation economy.
During Watts’ tenure as majority chief counsel, the subcommittee held 17 legislative and oversight hearings and multiple staff briefings on IP issues, ranging from the state of patent eligibility law in America to reforming the Digital Millennium Copyright Act of 1998. Under his leadership, the subcommittee passed the CASE Act, the Trademark Modernization Act, and the Protecting Lawful Streaming Act, three landmark bills that collectively represent the largest changes to IP law since the Leahy-Smith America Invents Act.
Earlier, Watts was chief immigration counsel to then-Senate Judiciary Committee Chairman Chuck Grassley (R-IA). He began his career with former Senator Jeff Sessions (R-AL) as a legislative counsel on the Subcommittee on Immigration and the National Interest, handling civil rights and civil liberties law, general tort law, bankruptcy, telecommunications, and IP issues for the senator.
Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
Lisa Larrimore Ouellette, Adam Mossoff, Dan Troy, Brad Watts
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of...
Does President Trump Have the Authority to Pause and Modify the Medicare Drug Price Negotiation Program?
John Shu, Jeff Stier, Dan Troy
Since its inception, the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program has been...
Time for a Checkup: Evaluating the Withdrawal of the Health Care Antitrust Guidelines
Adam Biegel, John D. Carroll, Richard A. Feinstein, Laurel Kilgour, Bernard A. Nigro, Barak D. Richman
In 1996, the FTC and DOJ issued Statements of Antitrust Enforcement Policy in Health Care. ...
FTC’s Interim Pharmacy Benefit Manager Report - Assessing Vigor
FTC’s Interim Pharmacy Benefit Manager Report - Assessing Vigor
Daniel J. Gilman, Rani A. Habash, Derek W. Moore, Mike Shor
On July 9th, the Federal Trade Commission released a Staff Interim Report on the Pharmacy...
FTC’s Interim Pharmacy Benefit Manager Report - Assessing Vigor
Daniel J. Gilman, Rani A. Habash, Derek W. Moore, Mike Shor
On July 9th, the Federal Trade Commission released a Staff Interim Report on the Pharmacy...
Fireside Chat with FTC Commissioner Melissa Holyoak
Svetlana Gans, Melissa Holyoak
Join us on Wednesday, July 10th at 12:00 PM ET for a special lunch panel...
Rutledge v. Pharm. Care Management Association - Post-Argument SCOTUScast
Max E. Schulman
On October 6, 2020, the Supreme Court heard oral arguments for Rutledge v. Pharmaceutical Care...